🔍

INDIAGLYCO - India Glycols

📊 NSE: INDIAGLYCO 🏢 Breweries & Distilleries 📅 Last Updated: 12/14/2025 7:57

📢 Recent Corporate Announcements

India Glycols Wins Tax Appeal; Penalty Reduced from ₹7.2 Lakh to ₹10,000

🟢 POSITIVE ⭐ 3/10

LEGAL 📅 15 Apr 2026, 09:33 PM

India Glycols Limited has successfully appealed a tax penalty order originally issued in November 2024. The Appellate Authority in Gujarat set aside the initial IGST penalty of ₹7,20,570. A nominal penalty of ₹10,000 was instead imposed due to a clerical error in an E-way bill. The company has decided to accept the minor penalty to avoid further litigation costs, resulting in a net positive legal outcome.

Appellate Authority set aside the original IGST penalty of ₹7,20,570
New nominal penalty of ₹10,000 imposed for clerical error in E-way bill
Company decided not to file further appeal due to low quantum of penalty
Order passed by Deputy Commissioner of State Tax, Appeal-4, Mehsana, Gujarat

💡 This is a minor positive development with negligible financial impact. Investors should treat this as a routine legal resolution and focus on core business performance.

India Glycols Demerger Update: NCLT Admits Second Motion Petition for Biopharma and Spirits Units

🟢 POSITIVE ⭐ 8/10

M&A 📅 10 Apr 2026, 08:47 PM

India Glycols Limited (IGL) has announced that the NCLT Allahabad Bench admitted its second motion petition on April 9, 2026, regarding its proposed Scheme of Arrangement. The scheme involves the demerger of business divisions into two new entities: Ennature Biopharma Limited and IGL Spirits Limited. The court has directed the company to issue statutory notices to authorities including SEBI and the Income Tax department, providing a 30-day window for representations. This procedural progress brings the company closer to completing its corporate restructuring aimed at unlocking value across its diverse business segments.

NCLT Allahabad Bench admitted the Second Motion Petition for the demerger scheme on April 9, 2026.
The restructuring involves demerging assets into Ennature Biopharma Limited and IGL Spirits Limited.
Regulatory authorities and the public have been granted 30 days to file representations or objections.
The next NCLT hearing for further proceedings is scheduled for May 21, 2026.
The scheme remains subject to final regulatory approvals and the outcome of the upcoming hearing.

💡 Investors should view this as a positive step toward value unlocking through the separation of the biopharma and spirits businesses. Monitor the outcome of the May 21, 2026, NCLT hearing for final approval timelines.

India Glycols Submits Quarterly Compliance Certificate for Dematerialization (Q4 FY26)

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 03 Apr 2026, 12:36 PM

India Glycols Limited has filed its quarterly compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. The filing confirms that for the quarter ended March 31, 2026, the company's Registrar and Share Transfer Agent, MCS Share Transfer Agent Limited, processed all dematerialization requests. The certificate verifies that security certificates were mutilated and cancelled, and the depository's name was updated in the records within the mandated 15-day timeframe. This is a standard administrative filing required by all listed companies in India.

Compliance certificate issued for the quarter ended March 31, 2026.
Confirmation that dematerialization requests were processed within 15 days of receipt.
Verification that security certificates were mutilated and cancelled as per SEBI guidelines.
Registrar and Share Transfer Agent (RTA) confirmed the substitution of the depository's name in company records.

💡 No action is required from investors as this is a routine regulatory compliance filing. Investors should continue to monitor the company's upcoming financial performance reports for the full fiscal year.

India Glycols Announces Trading Window Closure from April 1, 2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 26 Mar 2026, 06:43 PM

India Glycols Limited has informed the exchanges that its trading window for dealing in company securities will be closed starting April 1, 2026. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, ahead of the declaration of audited financial results for the fiscal year ending March 31, 2026. The window will remain shut until 48 hours after the financial results are officially announced. This is a standard regulatory procedure for listed companies to prevent insider trading during the period when sensitive financial data is being finalized.

Trading window closure effective from Wednesday, April 1, 2026
Closure pertains to the Audited Financial Results for the year ending March 31, 2026
Window to reopen 48 hours after the declaration of financial results
Compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015

💡 This is a routine regulatory filing and requires no immediate action from investors. Shareholders should look out for the future announcement of the specific date for the FY2026 earnings board meeting.

India Glycols Shareholders Approve Scheme of Arrangement with 100% Majority

🟢 POSITIVE ⭐ 8/10

M&A 📅 24 Mar 2026, 08:16 PM

Shareholders of India Glycols Limited have overwhelmingly approved a Scheme of Arrangement involving the restructuring of the company with Ennature Bio Pharma Limited and IGL Spirits Limited. In a court-convened meeting held on March 24, 2026, the special resolution received near-unanimous support, with 99.9999% of votes cast in favor. A total of 4.42 crore votes were polled, representing approximately 66.02% of the total shareholding. This restructuring is a strategic move likely aimed at separating business verticals to unlock shareholder value.

Special resolution for Scheme of Arrangement passed with 4,42,48,625 votes in favor and only 1 vote against.
The arrangement involves India Glycols (Demerged Company), Ennature Bio Pharma, and IGL Spirits (Resulting Companies).
Total voting participation represented 66.02% of the company's total 6.70 crore outstanding shares.
The meeting was conducted via video conferencing following orders from the NCLT Allahabad Bench.
100% of the Promoter and Promoter Group votes (3.99 crore shares) were cast in favor of the resolution.

💡 Investors should view this as a positive step toward corporate restructuring and value unlocking; keep a watch for the final NCLT sanction and the record date for share allotments in the resulting companies.

India Glycols Declares ₹7.50 Interim Dividend; Sets Record Date for March 23, 2026

🟢 POSITIVE ⭐ 7/10

DIVIDEND 📅 17 Mar 2026, 05:56 PM

India Glycols Limited has declared an interim dividend of ₹7.50 per equity share (150% of face value) for the financial year 2025-26. The company has fixed March 23, 2026, as the record date to determine eligibility for the payout. Tax will be deducted at source (TDS) at a standard rate of 10% for resident individuals with a valid PAN, while a higher rate of 20% applies if the PAN is not linked with Aadhaar. Shareholders must submit relevant tax exemption documents by the record date to benefit from lower withholding rates.

Interim dividend of ₹7.50 per share (150% of ₹5 face value) declared for FY 2025-26.
Record date for determining eligible shareholders is fixed as March 23, 2026.
Standard TDS of 10% for resident individuals with PAN; 20% for those without PAN or unlinked Aadhaar.
No TDS for resident individuals if the total dividend for the financial year does not exceed ₹10,000.
Non-resident shareholders may avail DTAA benefits by submitting TRC and Form 10F by the record date.

💡 Investors should ensure their PAN and Aadhaar are linked and submit tax-exemption forms like 15G/15H by March 23 to avoid higher TDS. To be eligible for the ₹7.50 dividend, shares must be held in the portfolio as of the record date.

India Glycols Declares Rs 7.5 Interim Dividend; Sets March 23 as Record Date

🟢 POSITIVE ⭐ 7/10

DIVIDEND 📅 17 Mar 2026, 04:05 PM

India Glycols Limited has announced an interim dividend of Rs 7.5 per equity share for the financial year 2025-26. This payout represents 150% of the face value of Rs 5 per share. The company has designated March 23, 2026, as the record date to identify eligible shareholders. The dividend is scheduled to be paid within 30 days from the declaration date of March 17, 2026.

Interim dividend of Rs 7.5 per equity share declared for FY 2025-26
Dividend payout represents 150% of the face value of Rs 5 per share
Record date for shareholder eligibility fixed as March 23, 2026
Payment to be completed within 30 days from the declaration date

💡 Investors seeking to benefit from this dividend should ensure they hold the stock before the ex-dividend date. The 150% payout reflects a healthy cash distribution to shareholders.

India Glycols Declares Interim Dividend of Rs 7.5 Per Share (150%)

🟢 POSITIVE ⭐ 7/10

DIVIDEND 📅 17 Mar 2026, 04:01 PM

India Glycols Limited has announced an interim dividend of Rs. 7.5 per equity share for the financial year 2025-26. This payout corresponds to 150% of the face value of Rs. 5 per share. The Board has established March 23, 2026, as the record date for identifying eligible shareholders. The disbursement will occur within 30 days of the declaration date, providing a direct cash return to investors.

Interim dividend of Rs. 7.5 per share declared for FY 2025-26.
Dividend payout represents 150% of the face value of Rs. 5.
Record date for shareholder eligibility set for March 23, 2026.
Payment to be completed within 30 days from March 17, 2026.

💡 Existing shareholders should hold their positions until the record date of March 23 to qualify for the payout. New investors interested in the dividend should ensure they purchase shares before the ex-dividend date.

India Glycols Receives Rs 38.88 Crore Interim Dividend from Clariant IGL JV

🟢 POSITIVE ⭐ 7/10

DIVIDEND 📅 17 Mar 2026, 02:44 PM

India Glycols Limited and its wholly-owned subsidiary have received a substantial interim dividend from their joint venture, Clariant IGL Specialty Chemical Private Limited. The JV declared a dividend of Rs 36,000 per share (3600%), resulting in a total gross receipt of Rs 38.88 crore for the group. Specifically, the parent company received Rs 36 crore while the subsidiary received Rs 2.88 crore. This significant cash inflow reflects the strong performance and liquidity of the joint venture entity.

Total gross dividend inflow of Rs 38.88 crore from JV Clariant IGL Specialty Chemical Private Limited
JV declared an interim dividend of Rs 36,000 per equity share of face value Rs 10
India Glycols holds a 45.37% direct stake and 3.63% via a subsidiary in the JV
Net of TDS, the group received approximately Rs 34.99 crore in cash on March 17, 2026

💡 This is a positive development for liquidity and non-operating income; investors should monitor if these gains are passed on as dividends to IGL shareholders or used for debt reduction.

India Glycols: ₹191.76 Cr Fine Set Aside; Penalty Reduced to ₹41 Cr in Customs Case

🟢 POSITIVE ⭐ 7/10

LEGAL 📅 13 Mar 2026, 08:04 PM

India Glycols Limited has received a favorable appellate order regarding a customs duty dispute from March 2024. The Appellate Authority has set aside a massive redemption fine of ₹191.76 crore and reduced the penalty from ₹82 crore to ₹41 crore. While the core duty demand of ₹33.43 crore plus interest remains upheld, the total potential liability has decreased significantly. The company intends to file a second appeal to contest the remaining confirmed amounts.

Redemption fine of ₹191.76 crore has been completely set aside by the Appellate Authority.
Penalty amount reduced by 50%, from ₹82 crore down to ₹41 crore.
Customs duty demand of ₹33.43 crore plus applicable interest remains upheld.
Company plans to file a second appeal against the remaining ₹74.43 crore (duty + penalty) plus interest.

💡 Investors should view this as a positive development as it significantly reduces a major contingent liability, though the remaining ₹74.43 crore plus interest should still be monitored through the next appeal phase.

CARE Places India Glycols on Rating Watch with Developing Implications Amid Demerger Plans

🔵 WATCH ⭐ 8/10

REGULATORY 📅 10 Mar 2026, 06:57 PM

CARE Ratings has placed India Glycols' 'CARE A-' long-term rating on 'Rating Watch with Developing Implications' due to the proposed demerger of its Biofuel, Potable Spirits, and Bio-pharma businesses. The company's financial profile is improving, supported by a ₹467 crore preferential issue in Q3FY26 which was primarily used for debt reduction. Performance for 9MFY26 shows 11% revenue growth to ₹3,239 crore with margins expanding to 15.04%. The restructuring is expected to be completed within six months, resulting in three separate entities to enhance management focus.

CARE A- rating placed on 'Rating Watch with Developing Implications' following the board-approved composite scheme of arrangement.
Raised ₹467 crore via preferential issue in Q3FY26, reducing total debt including LC acceptances to ₹1,793 crore as of January 2026.
9MFY26 revenue grew 11% YoY to ₹3,239 crore with PBILDT margins expanding significantly to 15.04%.
Net debt to PBILDT ratio is projected to improve to 2.5x-3.0x by FY26-end from 4.31x in FY25.
Demerger will split operations into IGL (Chemicals), IGL Spirits (Biofuels/Spirits), and Ennature Bio Pharma (Nutraceuticals).

💡 Investors should maintain a watch on the NCLT approval process for the demerger, which is expected to unlock value across different business segments. The substantial debt reduction and improving margins provide a positive cushion during this transition period.

India Glycols Board to Meet on March 17 to Consider Interim Dividend for FY 2025-26

🟢 POSITIVE ⭐ 7/10

DIVIDEND 📅 10 Mar 2026, 04:50 PM

India Glycols Limited has scheduled a Board of Directors meeting on March 17, 2026, to consider the declaration of an interim dividend for the financial year 2025-26. Following this announcement, the company has implemented a trading window closure for insiders from March 11 to March 19, 2026. This move indicates a potential cash payout to shareholders, reflecting the company's current financial health and commitment to returning value. Investors should watch for the specific dividend amount and record date following the meeting.

Board meeting scheduled for March 17, 2026, to consider interim dividend for FY 2025-26
Trading window for securities closed from March 11, 2026, to March 19, 2026
Meeting convened under Regulation 29 of SEBI (LODR) Regulations, 2015
The outcome of the meeting will determine the dividend payout ratio for the current fiscal year

💡 Investors should monitor the March 17 board meeting outcome for the dividend amount and record date to assess the yield. Existing shareholders may benefit from the potential payout, while new investors should evaluate the stock's valuation relative to the dividend.

India Glycols Schedules NCLT-Convened Creditors Meeting for Demerger on March 24, 2026

🟡 NEUTRAL ⭐ 7/10

M&A 📅 20 Feb 2026, 02:46 PM

India Glycols Limited (IGL) is progressing with its corporate restructuring plan to demerge businesses into Ennature Biopharma Limited and IGL Spirits Limited. Following orders from the NCLT Allahabad Bench, the company has scheduled a meeting of its unsecured creditors on March 24, 2026, to seek approval for the Scheme of Arrangement. This follows similar procedural steps for shareholders and is a mandatory regulatory requirement for the demerger to proceed. The remote e-voting for eligible creditors is set to take place between March 20 and March 23, 2026.

NCLT-convened meeting of unsecured creditors scheduled for March 24, 2026, via Video Conferencing.
Scheme involves the demerger of units into two resulting companies: Ennature Biopharma Limited and IGL Spirits Limited.
Remote e-voting period is set from March 20, 2026 (9:00 AM) to March 23, 2026 (5:00 PM).
The cut-off date for determining the eligibility of unsecured creditors to vote was November 15, 2025.

💡 Investors should track the outcome of these meetings as the demerger will lead to the creation of specialized entities for biopharma and spirits. No immediate action is required, but the restructuring is a key milestone for potential value unlocking.

India Glycols Schedules NCLT-Convened Meeting on March 24, 2026, for Business Demerger

🟢 POSITIVE ⭐ 9/10

M&A 📅 20 Feb 2026, 02:33 PM

India Glycols Limited (IGL) has announced a Court Convened Meeting on March 24, 2026, to seek shareholder approval for a major Scheme of Arrangement. The plan involves demerging specific business undertakings into two new entities: Ennature Biopharma Limited and IGL Spirits Limited. Shareholders as of the cut-off date of March 17, 2026, will be eligible to vote on the proposal. This restructuring is intended to streamline operations and potentially unlock value for shareholders by creating focused business units.

NCLT-convened meeting for equity shareholders scheduled for March 24, 2026, at 11:00 A.M. via video conferencing.
Proposed demerger of business segments into Ennature Biopharma Limited and IGL Spirits Limited.
Remote e-voting period is set from March 20, 2026, to March 23, 2026, with a cut-off date of March 17, 2026.
The scheme has already received 'No-objection' from NSE and 'No adverse observation' from BSE as of November 2025.
Special purpose financial statements for the period ending September 30, 2025, have been prepared for all involved entities.

💡 Investors should monitor the demerger ratio and the specific assets being transferred to evaluate the long-term value of the new entities. Shareholders are advised to participate in the e-voting process to support the corporate restructuring.

India Glycols Reschedules NCLT-Directed Shareholder Meeting to March 24, 2026

🟡 NEUTRAL ⭐ 6/10

M&A 📅 18 Feb 2026, 04:35 PM

India Glycols Limited has received a revised order from the NCLT Allahabad Bench regarding its proposed Scheme of Arrangement involving Ennature Biopharma and IGL Spirits. The meetings for equity shareholders and unsecured creditors, originally set for March 9, 2026, have been rescheduled to March 24, 2026. This administrative change was necessitated by the unavailability of the NCLT-appointed Chairperson on the original date. The meetings will be conducted via video conferencing to consider and approve the restructuring scheme.

NCLT Allahabad Bench approved rescheduling of shareholder and creditor meetings to March 24, 2026.
The original meeting date was March 9, 2026, but was changed due to the Chairperson's unavailability.
The Scheme of Arrangement involves India Glycols, Ennature Biopharma Limited, and IGL Spirits Limited.
Meetings will be held via video conferencing under Sections 230 to 232 of the Companies Act, 2013.
The rest of the NCLT order dated January 15, 2026, remains unchanged and valid.

💡 Investors should mark the new date of March 24, 2026, to participate in the voting process for the proposed demerger and arrangement. This is a routine administrative delay and does not reflect on the merits of the underlying transaction.

View All INDIAGLYCO Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Biofuels (BF) grew 54.5% YoY to INR 770 Cr in H1FY26. Potable Spirits (PS) grew 24.5% YoY to INR 338 Cr in Q2FY26. Bio-based Specialities and Performance Chemicals (BSPC) declined 22.8% YoY to INR 588 Cr in H1FY26 due to subdued pricing and demand in Chinese/SE Asian markets.

Geographic Revenue Split

Not disclosed in available documents, though the company notes management decisions to restrict supply to domestic markets due to subdued pricing in Chinese and South-East Asian markets.

Profitability Margins

Gross Revenue reached INR 9,052 Cr in FY25, up 13.9% from INR 7,944 Cr in FY24. PAT margin improved to 6.5% in H1FY26 from 5.7% in H1FY25. Net profit for FY25 was INR 180 Cr compared to INR 152 Cr in FY24, a 18.4% increase.

EBITDA Margin

EBITDA margin stood at 14.6% in H1FY26, expanding by 172 bps from 12.8% in H1FY25. Absolute EBITDA grew 25.1% YoY to INR 311 Cr. The company has seen a steady margin recovery from 11% in FY22 to nearly 15% in FY26.

Capital Expenditure

Planned capex of INR 175 Cr and INR 190 Cr for FY25 and FY26 respectively, primarily funded through term loans for distillery capacity enhancement and the New Specialities Unit (NSU). Gross Fixed Assets increased to INR 4,377 Cr in FY25 from INR 3,713 Cr in FY24.

Credit Rating & Borrowing

Credit rating maintained by CARE Ratings with an 'Adequate' liquidity profile. Interest coverage ratio was 3.15x in 9MFY25. Finance costs increased 23.7% YoY to INR 94 Cr in H1FY26 due to higher debt for capex.

⚙️ Operational Drivers

Raw Materials

Ethyl Alcohol (primary feedstock for BSPC), Grain/Molasses (for distillery), and various chemicals. Raw material costs are highly volatile and impact the spread for glycol products.

Import Sources

Sourced domestically within India, particularly from states like Uttar Pradesh and Uttarakhand for distillery operations.

Capacity Expansion

Distillery capacity is being enhanced with a capex of INR 365 Cr over two years. The New Specialities Unit (NSU) is currently ramping up operations as of Q2FY26 to drive future revenue.

Raw Material Costs

BSPC segment profitability is susceptible to the spread between glycol products and ethyl alcohol. PS segment margins were previously impacted by sharp escalations in ethanol and material costs.

Manufacturing Efficiency

EBITDA margin expansion of 216 bps in Q2FY26 indicates improved operational efficiency and better product mix.

📈 Strategic Growth

Expected Growth Rate

11-14%

Growth Strategy

Scaling up distillery facilities to supply ethanol to Oil Marketing Companies (OMCs), ramping up the New Specialities Unit (NSU), and expanding the Potable Spirits portfolio with in-house brands. The company is also leveraging its JV with Clariant for bio-based specialities.

Products & Services

Bio-based glycols, Ethanol (for OMCs), Country Liquor, IMFL (Spirits), Industrial Gases, Sugar, and Nutraceuticals (Ennature Biopharma).

Brand Portfolio

Zumba Lemoni, Soulmate Blu, Amazing Vodka (Potable Spirits).

New Products/Services

Launched in-house brands Zumba Lemoni and Soulmate Blu; planning to launch a new Brandy brand to strengthen the Potable Spirits segment.

Market Expansion

Strengthening footprint in the Paramilitary business and institutional channels for Potable Spirits.

Strategic Alliances

Joint Venture with Clariant (Clariant IGL) which contributed INR 30 Cr to PAT in H1FY26, a 40.1% YoY increase.

🌍 External Factors

Industry Trends

The Indian chemical industry is expected to grow to USD 300 billion by 2025. The liquor industry shows strong potential with volumes of 350 million cases, while the government's ethanol blending mandate is driving the Biofuel segment.

Competitive Landscape

Competes with traditional petrochemical-based glycol producers and other distillery-based chemical companies in India.

Competitive Moat

Moat is built on green technology-based manufacturing (bio-based vs petro-based) and a strong market position in the regulated liquor industry in North India. Sustainability is driven by the global shift toward renewable chemicals.

Macro Economic Sensitivity

Highly sensitive to global chemical cycles and crude oil prices which affect substitute glycol pricing.

Consumer Behavior

Shift toward premiumization in the Potable Spirits segment and increasing demand for sustainable/green chemicals in global supply chains.

Geopolitical Risks

Trade tensions and global supply chain shifts (China+1) are benefiting the Indian chemical sector, though subdued demand in China currently pressures export volumes.

⚖️ Regulatory & Governance

Industry Regulations

Highly regulated liquor industry where states control production, sales, and duty structures. Ethanol prices for OMCs are also subject to government mandates.

Environmental Compliance

Focus on green technology-based chemicals; specific ESG costs not disclosed.

Taxation Policy Impact

Tax expenses for H1FY26 were INR 36 Cr on a PBT of INR 174 Cr, representing an effective tax rate of approximately 20.7%.

⚠️ Risk Analysis

Key Uncertainties

Volatility in the spread between ethyl alcohol and glycol prices; potential introduction of prohibition laws in key states; and the successful ramp-up of the NSU unit.